Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
Skye Montoya, Jessie Bourcier, Meghan C. Thompson, Mark Noviski, May Tan, Eric Wang, Xiaoli Mi, Nivetha Brathaban, Carla Barrientos Risso, Daniel Tsai, Jordan Ye, Jacob Jahn, Gabriel Pardo, Lee Cabuhat, Ryan Q. Notti, Alejandro Pardo, Maurizio Affer, Stephanie Yung, James Luliano, Janine Powers, Daniel Robbins, Vindhya Nawaratne, Tulasigeri M. Totiger, Camila Pena-Velasquez, Joanna Rhodes, Andrew D. Zelenetz, Lindsey E. Roeker, Hao Lu, Adam J. Linley, Anthony R. Mato, Omar Abdel‐Wahab, Justin Taylor
Topics & Concepts
Bruton's tyrosine kinaseIbrutinibBiologyTyrosine kinaseCancer researchMedicineImmunologyChronic lymphocytic leukemiaGeneticsSignal transductionLeukemiaChronic Lymphocytic Leukemia ResearchChronic Myeloid Leukemia TreatmentsChromatin Remodeling and Cancer